Jpmorgan Chase & CO Axogen, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Axogen, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 275,998 shares of AXGN stock, worth $3.01 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
275,998
Previous 310,568
11.13%
Holding current value
$3.01 Million
Previous $5.12 Million
0.25%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding AXGN
# of Institutions
191Shares Held
39.2MCall Options Held
61.7KPut Options Held
42.8K-
First Light Asset Management, LLC Edina, MN4.47MShares$48.7 Million10.62% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$35.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.6MShares$28.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$27.6 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO1.59MShares$17.3 Million0.54% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $460M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...